title: Diagnostic and therapeutic challenges.
authors.affiliation: Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
authors.forename: Elham
authors.initials: E
authors.lastname: Hatef
authors.forename: Mohamed
authors.initials: M
authors.lastname: Ibrahim
authors.forename: Quan Dong
authors.initials: QD
authors.lastname: Nguyen
authors.forename: Diana V
authors.initials: DV
authors.lastname: Do
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Davis
authors.forename: Kourous A
authors.initials: KA
authors.lastname: Rezaei
authors.forename: Jaclyn L
authors.initials: JL
authors.lastname: Kovach
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D005260:Female; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D006801:Humans; D058449:Intravitreal Injections; D000069579:Ranibizumab; D012167:Retinal Perforations / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D055213:Retinal Pigment Epithelium / Q000187:drug effects*; D041623:Tomography, Optical Coherence; D014786:Vision Disorders / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D014792:Visual Acuity / Q000502:physiology; D057135:Wet Macular Degeneration / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069579:Ranibizumab